Loading clinical trials...
Loading clinical trials...
Human urinary kallidinogenase can promote the establishment of collateral circulation in the ischemic penumbra due to the stenosis or occlusion of middle cerebral artery and then increase the perfusion.
Patients with acute ischemic stroke will be given human urinary kallidinogenase .Then we will estimate the cerebral collateral circulation in ischemic regions and final infarct volume, comparing with traditional therapy such as Shuxuening injection, which will provide new evidence for the treatment of ischemic stroke. Perfusion Weighted Imaging(PWI) could be a method to reflect the infarction center and low perfusion of tissue.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Department of Neurolgy,Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Start Date
January 1, 2013
Primary Completion Date
June 1, 2014
Completion Date
June 1, 2014
Last Updated
October 8, 2014
120
ACTUAL participants
Human Urinary Kallidinogenase
DRUG
Shuxuening injection
DRUG
Lead Sponsor
XuanwuH 2
NCT06757764
NCT07140406
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07121088